Eun-Kee Park1, Paul S Thomas, Anthony R Johnson, Deborah H Yates. 1. Research and Education Unit, Workers' Compensation (Dust Diseases) Board, School of Medical Sciences, Faculty of Medicine, University of New South Wales, and Department of Thoracic Medicine, St Vincent's Hospital, Darlinghurst, Sydney, Australia.
Abstract
PURPOSE: Serum osteopontin levels in patients with malignant mesothelioma have been reported to be higher than in healthy subjects. This study assessed serum osteopontin levels in an asbestos-exposed population to test whether nonmalignant asbestos-related disorders could influence osteopontin levels. EXPERIMENTAL DESIGN: This cross-sectional study evaluated serum osteopontin levels in 525 male subjects. Subjects were classified into six different diagnostic groups, including asbestosis (n=23), silicosis (n=20), diffuse pleural thickening (n=110), asbestosis and diffuse pleural thickening (n=13), pleural plaques (n=142), and healthy subjects with a history of asbestos exposure (n=217). RESULTS: Mean serum osteopontin levels differed among the six groups (P<0.0001). Mean osteopontin values of the healthy individuals exposed to asbestos were significantly different from that of subjects with asbestosis (P<0.001) and diffuse pleural thickening (P<0.001). There was a significant difference in mean serum levels of osteopontin in healthy individuals exposed to asbestos (n=217) compared with the group mean of all subjects with asbestos-related disorders (n=288; P<0.0001). CONCLUSIONS: Our results suggest that osteopontin levels are elevated in subjects with asbestos-related disorders without malignant mesothelioma. These data indicate that osteopontin, although reported to be useful for detecting malignant mesothelioma in asbestos-exposed individuals, may be influenced by nonmalignant processes.
PURPOSE: Serum osteopontin levels in patients with malignant mesothelioma have been reported to be higher than in healthy subjects. This study assessed serum osteopontin levels in an asbestos-exposed population to test whether nonmalignant asbestos-related disorders could influence osteopontin levels. EXPERIMENTAL DESIGN: This cross-sectional study evaluated serum osteopontin levels in 525 male subjects. Subjects were classified into six different diagnostic groups, including asbestosis (n=23), silicosis (n=20), diffuse pleural thickening (n=110), asbestosis and diffuse pleural thickening (n=13), pleural plaques (n=142), and healthy subjects with a history of asbestos exposure (n=217). RESULTS: Mean serum osteopontin levels differed among the six groups (P<0.0001). Mean osteopontin values of the healthy individuals exposed to asbestos were significantly different from that of subjects with asbestosis (P<0.001) and diffuse pleural thickening (P<0.001). There was a significant difference in mean serum levels of osteopontin in healthy individuals exposed to asbestos (n=217) compared with the group mean of all subjects with asbestos-related disorders (n=288; P<0.0001). CONCLUSIONS: Our results suggest that osteopontin levels are elevated in subjects with asbestos-related disorders without malignant mesothelioma. These data indicate that osteopontin, although reported to be useful for detecting malignant mesothelioma in asbestos-exposed individuals, may be influenced by nonmalignant processes.
Authors: Christopher J Wingard; Dianne M Walters; Brook L Cathey; Susana C Hilderbrand; Pranita Katwa; Sijie Lin; Pu Chun Ke; Ramakrishna Podila; Apparao Rao; Robert M Lust; Jared M Brown Journal: Nanotoxicology Date: 2010-11-03 Impact factor: 5.913
Authors: Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan Journal: Lung Date: 2013-10-30 Impact factor: 2.584
Authors: Clementina Mesaros; Andrew J Worth; Nathaniel W Snyder; Melpo Christofidou-Solomidou; Anil Vachani; Steven M Albelda; Ian A Blair Journal: Bioanalysis Date: 2015 Impact factor: 2.681
Authors: Michael K Felten; Khaled Khatab; Lars Knoll; Thomas Schettgen; Hendrik Müller-Berndorff; Thomas Kraus Journal: Int Arch Occup Environ Health Date: 2013-02-20 Impact factor: 3.015
Authors: A Bonotti; R Foddis; S Landi; O Melaiu; C De Santi; L Giusti; E Donadio; F Ciregia; M R Mazzoni; A Lucacchini; M Bovenzi; M Comar; E Pantani; A Pistelli; A Cristaudo Journal: Dis Markers Date: 2017-02-28 Impact factor: 3.434